Eliminating hepatitis C infection in Australia through harm reduction, education and treatment scale up
Hepatitis C affects over 230,000 people in Australia. Currently only 1 to 2 per cent of people with chronic HCV are treated annually. In 2016, the World Health Organization set targets to reduce new HCV infections by 80 per cent, reduce deaths due to HCV by 65 per cent, and eliminate HCV as a public health problem by 2030.
With new, effective non-interferon-based treatments, it should be possible for Australia to achieve these elimination targets. Key to our success in reducing HCV-related deaths and new infections in Australia will be the upscaling of treatment for all people with chronic HCV infection, including those currently transmitting HCV who are chiefly people who inject drugs. New community-based treatment programs in primary care, drug and alcohol services and community organisations are being rolled out locally.
This project is open to students
Improve the quality of care
The project will aim to explore:
- improved harm reduction strategies
- workforce development and health service delivery
- supports needed for prescribers to start treatment.
The outcomes will help facilitate treatment uptake and improve the quality of care.
Open to
- Honours
- Masters by research
- PhD
Supervisors
Contact
Project contacts
Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow
Project team
Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow
More student projects
View 61 more
The Gist: a pornography education program to improve sexual health and wellbeing in young people
The Gist helps young people navigate sex and relationships. It includes a website, educational videos and in-person education sessions in schools and youth services in Victoria.
Bridging the gap in pre-eclampsia research through evidence surveillance
Accelerating Innovation for Mothers (AIM) 2.0
Globally, approximately 287,000 women die every year from pregnancy-related conditions and complications, with most of these deaths occurring in low- and middle-income countries (LMICs). Although investment in global maternal health has increased in the past 30 years, research and development (R&D) of new products has been a neglected area.
Why study at Burnet?
When you study at Burnet, you broaden your impact working across our three Institute-wide programs: Disease Elimination; Health Security and Pandemic Preparedness; Maternal, Child and Adolescent Health.
Train with internationally recognised experts in a structured student support system, and gain a holistic research experience along the way.